1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Chunghwa Chemical Synthesis & Biotech Co., Ltd.

Chunghwa Chemical Synthesis & Biotech Co., Ltd.

1762.TW
Chunghwa Chemical Synthesis & Biotech Co., Ltd.TW flagTaiwan Stock Exchange
38.15
TWD
-1.50
- -
2.93BMarket Cap
Chunghwa Chemical Synthesis & Biotech Co., Ltd.
1762.TW
(Taiwan Stock Exchange)

Recent

price

38.15

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
16.76
15.06
17.02
13.45
12.21
14.98
15.45
15.06
13.14
14.91
19.9
24.94
27.3
26.9
24.07
- -
14.47
Revenue per Share
2.62
2.2
2.32
1.25
0.19
3.98
0.78
1.11
3.02
1.51
6.86
5.17
6.01
3.42
0.95
- -
-4.38
Basic EPS, GAAP
3.14
0.87
-6.59
0.45
-1.59
-0.64
1.89
-8.33
1.82
1.98
-0.71
-2.4
4.61
-6.68
6.48
- -
1.44
Free Cash Flow per Basic Share
2.46
2
1.5
1.59
1
0.5
1.5
0.5
0.5
1.2
0.8
1.5
1.3
1.3
1.11
- -
- -
Dividend per Share
14.32
13.15
13.88
16.79
12.44
15.87
14.74
15.29
17.14
17.17
23.28
27.21
31.56
32.49
44.65
- -
39.82
Book Value per Share
23.56
21.18
22.22
22.06
20.82
24.01
22.83
23.44
25.55
25.97
32.2
37.29
41.07
43.12
59.89
- -
55.46
Tangible Book Value per Share
71
78
78
78
78
78
78
78
78
78
78
78
78
78
56
- -
56
Basic Weighted Avg Shares
1,197
1,168
1,320
1,043
947
1,162
1,199
1,168
1,019
1,157
1,544
1,935
2,117
2,086
1,347
805
805
Sales/Revenue/Turnover
17.18
14.28
16.07
9.46
2.47
8.56
8.19
6.69
3.03
10.47
17.42
23.61
21.03
13.46
0.47
-39.7
-39.7
Operating Margin (%)
62
65
69
83
96
103
115
134
135
130
131
132
169
193
199
191
191
Depreciation Expense
187
171
180
97
15
308
60
86
234
117
532
401
466
265
53
-244
-244
Net Income, GAAP
9.9
10.31
14.49
14.75
60.66
8.27
35.35
21.59
2.48
18.52
18.18
19.41
20.09
20.56
7.32
- -
- -
Effective Tax Rate (%)
15.62
14.64
13.64
9.28
1.54
26.53
5.03
7.34
22.98
10.12
34.46
20.72
22
12.7
3.94
-30.3
-30.3
Profit Margin (%)
342
307
185
136
541
229
117
219
188
111
601
722
835
956
1,016
702
702
Working Capital
20
- -
515
540
650
130
100
567
567
603
1
601
501
704
704
603
603
LT Debt
1,683
1,643
1,723
1,711
1,616
1,864
1,771
1,821
1,984
2,015
2,499
2,894
3,193
3,350
3,357
3,087
3,087
Total Equity
10.67
8.22
8.16
3.24
0.34
3.49
2.67
2.3
1.04
3.45
7.95
11.71
9.45
5.3
0.13
- -
- -
Return on Invested Capital (%)
10.13
14.43
11.52
5.05
0.89
15.89
3.72
4.58
10.87
5.76
26.52
17.25
16
8.27
2.05
- -
- -
Return on Capital (%)
18.95
16.74
17.18
8.14
1.29
28.09
5.08
7.37
18.63
8.79
33.9
20.47
20.44
10.67
2.11
-10.34
-10.34
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
ST Debt
255
204
203
LT Borrowings
600
600
600
LT Finance Leases
2
3
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
78
77
77
Market Capitalization
1,604
1,438
1,363

Working Capital

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
Total Current Assets
1,295
1,171
1,059
Cash, Cash Equivalents & STI
214
253
216
Accounts Receivable, Net
226
109
92
Inventories
825
785
718
Total Current Liabilities
460
351
357
Payables & Accruals
- -
- -
- -
ST Debt
255
204
203
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.56%
4.65%
-8.03%
Free Cash Flow
-173.01%
-108.9%
-77.88%
Net Income, GAAP
-25.19%
-138.27%
-559.81%
Sales/Revenue/Turnover
-0.76%
-8.47%
-40.26%
Total Cash Common Dividend
- -
- -
-76.25%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
765
526
339
455
2,086
2024
252
461
348
286
1,347
2025
193
344
154
113
805

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
2.3
0.38
0.15
- -
3.42
2024
0.52
0.27
-0.11
- -
0.95
2025
0.13
-1.21
-0.77
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1.3
2024
- -
- -
- -
- -
1.11
2025
- -
- -
- -
- -
- -
Similar Companies
HST Global, Inc. (HSTC)
Atossa Therapeutics, Inc. (ATOS)
Vectorite Biomedical Inc. (4170.TWO)
CymaBay Therapeutics, Inc. (CBAY)
Longevity Health Holdings Inc. (XAGE)
Recce Pharmaceuticals Ltd (RECEF)
Business
Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW) manufactures and sells active pharmaceutical ingredients (APIs) for the global pharmaceutical industry. The company produces a wide range of biotech and chemical synthetic products, including immunosuppressants such as tacrolimus, everolimus, rapamycin and mycophenolate mofetil; antifungals such as fluconazole, caspofungin and anidulafungin; cardiovascular drugs such as pravastatin, trandolapril and edoxaban tosylate monohydrate; oncology agents; pain management products including methocarbamol and skeletal muscle relaxants; antidiabetics such as glipizide; antihistamines like olopatadine and dexbromopheniramine maleate; anti-anxiety agents; laxatives; antiseptics; antiulcerants; hypolipidemics; antineoplastics; antihyperlipidemics; peptide drugs such as abaloparatide; anti-virus agents; immunomodulating agents including baricitinib and eltrombopag olamine; and others such as guaifenesin, eslicarbazepine acetate, brivaracetam, difelikefalin acetate and sugammadex sodium. It operates cGMP-compliant facilities approved by the FDA and EU, provides contract manufacturing and research services, and distributes products domestically in Taiwan and internationally to Asia, the Americas and Europe. Founded in 1964 and headquartered in New Taipei City, Taiwan, the company maintains a manufacturing site spanning 8.7 acres in the Taipei suburb and employs approximately 243 people. In recent developments, Chunghwa Chemical Synthesis & Biotech successfully completed multiple customer audits in 2025, including those for ethyl icosapentate and everolimus in September, sugammadex sodium in August, tacrolimus in May from an Indian client, caspofungin and trandolapril in May from a Greek client, rapamycin in April from a Japanese client, and mycophenolate mofetil in April and March from Indian clients; it also authorized a share buyback plan in April 2025 and received the 2025 Corporate Sustainability Report Award in November.